Lyra Therapeutics (LYRA) Other Non-Current Assets (2019 - 2025)
Quarterly Other Non-Current Assets changed 0.0% to $2.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.0 million through Dec 2025, changed 0.0% year-over-year, with the annual reading at $2.0 million for FY2025, 0.0% changed from the prior year.
Lyra Therapeutics' Other Non-Current Assets history spans 7 years, with the latest figure at $2.0 million for Q4 2025.
- Other Non-Current Assets came in at $2.0 million for Q4 2025, roughly flat from $2.0 million in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $7.5 million in Q3 2023 to a low of $243000.0 in Q2 2021.
- The 5-year median for Other Non-Current Assets is $1.4 million (2023), against an average of $1.7 million.
- Year-over-year, Other Non-Current Assets surged 585.31% in 2023 and then tumbled 73.31% in 2024.
- Lyra Therapeutics' Other Non-Current Assets stood at $700000.0 in 2021, then skyrocketed by 368.71% to $3.3 million in 2022, then plummeted by 57.57% to $1.4 million in 2023, then soared by 43.18% to $2.0 million in 2024, then changed by 0.0% to $2.0 million in 2025.
- Per Business Quant, the three most recent readings for LYRA's Other Non-Current Assets are $2.0 million (Q4 2025), $2.0 million (Q3 2025), and $2.0 million (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | - |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | 12.40 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | 60,000.00 |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 1.26 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 2.13 Bn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 63.55 Mn |
| 10 | Lyra Therapeutics | - | - | - | 1.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.99 Mn |
| Sep 30, 2025 | 1.99 Mn |
| Jun 30, 2025 | 1.99 Mn |
| Mar 31, 2025 | 1.99 Mn |
| Dec 31, 2024 | 1.99 Mn |
| Sep 30, 2024 | 1.99 Mn |
| Jun 30, 2024 | 1.99 Mn |
| Mar 31, 2024 | 683,000.00 |
| Dec 31, 2023 | 1.39 Mn |
| Sep 30, 2023 | 7.46 Mn |
| Jun 30, 2023 | 1.09 Mn |
| Mar 31, 2023 | 1.39 Mn |
| Dec 31, 2022 | 3.28 Mn |
| Sep 30, 2022 | 1.09 Mn |
| Jun 30, 2022 | 1.09 Mn |
| Mar 31, 2022 | 300,000.00 |
| Dec 31, 2021 | 700,000.00 |
| Sep 30, 2021 | 329,000.00 |
| Jun 30, 2021 | 243,000.00 |
| Mar 31, 2021 | 329,000.00 |
| Dec 31, 2020 | 300,000.00 |
| Sep 30, 2020 | 329,000.00 |
| Jun 30, 2020 | 329,000.00 |
| Mar 31, 2020 | 300,000.00 |
| Dec 31, 2019 | 1.10 Mn |